Lab Report Analysis - Mathurbhai Pateliya (50 yr/M, 20/06/2026)

ABNORMAL VALUES SUMMARY

PRIMARY DIAGNOSIS

Obstructive (Cholestatic) Jaundice

• Direct (conjugated) bilirubin is the dominant fraction - Direct 10.0 out of Total 12.0 mg/dL = 83% of total bilirubin is direct. In obstructive jaundice, direct bilirubin accounts for >50% of the total bilirubin elevation (Current Surgical Therapy 14e).
• Bile pigments AND bile salts both present in urine - conjugated bilirubin is water-soluble and spills into urine; this is a hallmark of post-hepatic obstruction.
• SGPT moderately elevated at 90 U/L (2.25x ULN) - mild-moderate liver injury. In obstructive jaundice, ALT elevation is typically well below the thousands seen in viral/ischemic hepatitis (Current Surgical Therapy 14e). This pattern fits.

1. Choledocholithiasis (CBD stone) - most common benign cause; typically painful
2. Cholangiocarcinoma or pancreatic head carcinoma - painless progressive jaundice; must be ruled out at age 50
3. Biliary stricture
4. Cholangitis (if fever is present)

SECONDARY FINDINGS

Mild Normocytic Anaemia

• Hb 12.9, RBC 3.92, PCV 37.6% - all mildly low
• MCV 95.92 fL (normal range 80-96) - normocytic
• This can be due to chronic disease/liver disease, or a component of haemolysis (indirect bilirubin is also mildly raised at 2.0 mg/dL)

Urinary Tract Infection (likely)

• 12-14 pus cells/hpf (normal <5) with raised epithelial cells (6-8)
• Bacteria noted (though "dashes" may mean trace/present)
• No red cells, casts, or crystals

RECOMMENDED WORKUP (Further Investigations)

1. Abdominal Ultrasound (USG) - First-line, non-invasive; assesses bile duct dilation, gallstones, liver parenchyma, pancreatic masses (Goldman-Cecil Medicine)
2. Alkaline Phosphatase (ALP) + GGT - Key cholestatic enzymes; not done in this report. A 3-4x elevation in ALP supports cholestasis
3. MRCP (Magnetic Resonance Cholangiopancreatography) - Best non-invasive imaging for biliary tree
4. Serum Albumin + Prothrombin Time - Assess liver synthetic function
5. Hepatitis B/C serology - Rule out viral hepatitis contributing to jaundice
6. CA 19-9, CEA - Tumour markers if malignancy suspected
7. Urine culture and sensitivity - Confirm UTI organism and guide antibiotic choice
8. ERCP - Diagnostic and therapeutic if CBD stone confirmed

TREATMENT APPROACH

1. Obstructive Jaundice

• Definitive treatment depends on the cause - must image first
• If CBD stone: ERCP with sphincterotomy and stone removal is the treatment of choice
• If malignancy: surgical resection (Whipple procedure for pancreatic head) or biliary stenting for palliation
• Ursodeoxycholic acid may be used to relieve cholestasis symptoms
• Treat pruritus (from bile salt deposition): cholestyramine or antihistamines
• Ensure vitamin K supplementation (fat-soluble vitamin absorption is impaired with bile duct obstruction)
• Monitor for cholangitis (fever, RUQ pain, jaundice = Charcot's triad) - if present, broad-spectrum IV antibiotics + urgent biliary drainage

2. Urinary Tract Infection

• Urine culture result awaited
• Empirical oral antibiotic: Nitrofurantoin 100 mg BD x 5 days or Co-trimoxazole or Ciprofloxacin 500 mg BD x 3-5 days (pending culture)
• Increased fluid intake

3. Anaemia

• Investigate cause further (iron studies, B12/folate if needed)
• Treat underlying liver/biliary disease

IMMEDIATE CLINICAL PRIORITIES

This patient needs urgent imaging (USG abdomen) today. A Total Bilirubin of 12 mg/dL is severely elevated and the cause must be established urgently. If the patient has fever and/or right upper quadrant pain, cholangitis must be ruled out - which is a medical emergency requiring hospital admission and IV antibiotics.

• Fever and chills (suggests cholangitis)
• Clay/pale-colored stools (complete biliary obstruction)
• Dark tea-colored urine (already confirmed by urinalysis)
• Right upper quadrant or epigastric pain
• Weight loss (suggests malignancy)
• Itching/pruritus (bile salt deposition)

Disclaimer: This analysis is for informational purposes and should be reviewed by the treating physician. Clinical correlation and further investigations are mandatory before diagnosis confirmation and definitive treatment.

Imaging Findings: CBD Stone vs. Pancreatic Cancer

STEP 1 - Start with Abdominal Ultrasound (USG)

CBD Stone on USG

• Echogenic (bright/hyperechoic) focus within the duct lumen - seen in both longitudinal and transverse planes
• Acoustic shadowing posterior to the stone (dark shadow below the bright spot)
• CBD dilatation (>6 mm is significant; >8 mm strongly suggests obstruction)
• Gallstones may also be visible in the gallbladder
• USG sensitivity for CBD stones: 50-80%, specificity ~95%
• A CBD diameter <4 mm carries a high negative predictive value for stones

Above: (A) Transabdominal USG - echogenic stone with shadowing in the CBD. (B) EUS - stone in CBD adjacent to portal vein (PV). - Grainger & Allison's Diagnostic Radiology

Pancreatic Cancer on USG

• Hypoechoic (dark) solid mass in the head of the pancreas
• CBD dilation + main pancreatic duct (MPD) dilation visible together
• Gallbladder may be dilated and palpable (Courvoisier's sign)
• USG is often limited by bowel gas for deep pancreatic lesions - not reliable enough to exclude cancer

STEP 2 - MRCP / CT Abdomen (Second-line, Definitive)

CBD Stone on MRCP

• Filling defect (dark rounded signal void) within the bright bile duct on T2 images
• Meniscus sign: crescent of bile around the stone
• No pancreatic duct dilation - this is key
• The CBD ends in a smooth, rounded obstruction
• MRCP pooled sensitivity 92-94%, specificity 99% for cholelithiasis

Above: MRCP - single CBD stone (arrow) appearing as a dark filling defect in the bright bile duct column. - Grainger & Allison's Diagnostic Radiology

Pancreatic Cancer on CT/MRCP - The KEY Signs

• Hypoattenuating (hypodense) mass in the pancreatic head that enhances poorly compared to surrounding normal pancreatic tissue
• The tumour is hypovascular - this is best seen in the pancreatic parenchymal phase (~40 sec after contrast)
• 11% of tumours are isoattenuating on CT and may be invisible - rely on indirect signs then

Above: CT (A,B,C) fails to show a mass but reveals loss of lobulation and abrupt duct cut-off (arrow). MRI T1 (D) and DWI (E) clearly show the hypointense mass. MRCP (F) shows classic double duct sign with dilated CBD and pancreatic duct converging. - Grainger & Allison's Diagnostic Radiology

HEAD-TO-HEAD COMPARISON TABLE

STEP 3 - EUS (Endoscopic Ultrasound) - If Still Uncertain

• Sensitivity >90% for CBD stones, higher than transabdominal USG
• For pancreatic cancer: allows direct visualisation and EUS-guided fine needle aspiration (FNA) for tissue diagnosis - this is how you confirm cancer histologically
• Also assesses regional lymph nodes and vascular involvement

STEP 4 - ERCP - Therapeutic, not just Diagnostic

• If CBD stone confirmed on MRCP/EUS: proceed to ERCP + sphincterotomy + stone extraction
• If stricture with suspicion of malignancy: ERCP allows biliary stenting for palliation + brush cytology biopsy
• For pancreatic cancer, ERCP also shows the "tight shouldered stricture" of the distal CBD

Recommended Sequence for This Patient

USG Abdomen (today, urgent)
        |
   Stone seen?  →  Yes → ERCP (diagnostic + therapeutic)
        |
        No / Inconclusive
        |
      MRCP
        |
   Double duct sign / Pancreatic mass? → Yes → Contrast CT Abdomen for staging
                                                + EUS-FNA for tissue diagnosis
                                                + CA 19-9, CEA markers
        |
        No → Consider other causes (cholangiocarcinoma, stricture, ampullary carcinoma)